Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
N/A N=513 Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: 28 Day Mortality in Pediatric ARDS. — 44 Participants — p=<0.05
Phase 2 N=158 Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Phase 2 N=42 Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Covid19
Primary: Change From Baseline in High-sensitivity Troponin T — 1.12; 1.01 ng/mL — p=0.29
Phase 2 N=5 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Lung Injury, Acute
Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute
Phase 2 N=66 Add-on Reparixin in Adult Patients With ARDS
Acute Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) From Baseline to Day 7 of Treatment — -5.3; -6.6 Index — p=0.735
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Phase 2 N=61 LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Acute Respiratory Distress Syndrome (ARDS)
Primary: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio — 320; 334; 376; 336 SpO2/FiO2 Ratio — p=0.02
Phase 2 N=54 Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Asthma, Aspirin-Induced
Primary: Change From Baseline in Sinonasal Outcome Test-22 Score — -6.7; -13.7 units on a scale
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
N/A N=139 The Role of Circulating Soluble CD74 in Acute Lung Injury
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 2 N=448 Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Acute Respiratory Distress Syndrome · Coronavirus Infection
Primary: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High…
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
Phase 3 N=99 Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Acute Myocardial Infarction
Primary: Acute Phase Response (CRP Levels) — 60.03; 86.35; 213.75 mg x day/L (milligram x day/liter)
Phase 2 N=37 Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Clinically Significant Treatment Emergent Events — 37; 30; 22; 20 Number of patients
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
N/A N=112 ARB, ACEi, DRi Effects on COVID-19 Course Disease
Hypertension · COVID-19
Primary: Level of BP in mm Hg — 136; 138; 34; 82 mm Hg
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
Phase 1 N=18 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
Phase 1 N=9 Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
Phase 2 N=132 A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Respiratory Distress Syndrome, Adult
Primary: Ventilator-free Days During Days 1-28 — 10.8; 10.7 Days
Phase 4 N=128 ARIA (Atacand Renoprotection In NephropAthy Pt.)
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
N/A N=306 Advancing Symptom Alleviation With Palliative Treatment
Heart Failure · Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: Function Assessment of Chronic Illness Therapy-General (FACT-G) — 59.0; 54.0 score on a scale
N/A N=982 ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 173 participants